Nasal Cavity and Paranasal Sinus Carcinoma

Diseases /

Nasal Cavity and Paranasal Sinus Carcinoma

Back to Diseases List

Associated Genetic Biomarkers

ABL1
ABL1 Amplification
ABL1 Fusion
ABL1 Mutation
BRAF
BRAF Amplification
BRAF Mutation
CDKN2A No Expression
DDR2
DDR2 Amplification
DDR2 Mutation
EGFR
EGFR Amplification
EGFR Mutation
EPHA2
EPHA2 Amplification
EPHA2 Mutation
ERBB2
ERBB2 Amplification
ERBB2 Mutation

ERBB4
ERBB4 Amplification
ERBB4 Loss
ERBB4 Mutation
FGFR1
FGFR1 Amplification
FGFR1 Fusion
FGFR1 Mutation
FGFR2
FGFR2 Amplification

FGFR2 Fusion
FGFR2 Mutation
FLT1
FLT1 Amplification
FLT1 Mutation
FLT4
FLT4 Amplification
FLT4 Mutation
FRK
FRK Mutation

HPV Negative
KDR
KDR Amplification
KDR Mutation
KIT
KIT Amplification
KIT Fusion
KIT Mutation
MAPK11
MAPK11 Amplification

MAPK11 Mutation
PDGFRA
PDGFRA Amplification
PDGFRA Fusion
PDGFRA Mutation
PDGFRB
PDGFRB Amplification
PDGFRB Fusion
PDGFRB Mutation
RAF1

RAF1 Amplification
RAF1 Mutation
RET
RET Amplification
RET Fusion
RET Mutation
TEK
TEK Mutation
TRNAK2
TRNAK2 Mutation

VEGFA
VEGFA Amplification
VEGFB
VEGFB Amplification
VEGFC
VEGFC Amplification

Overview

Nasal cavity and paranasal sinus carcinomas most frequently harbor alterations in TP53, CDKN2A, PTEN, PIK3CA, and KMT2D [2].

Most Commonly Altered Genes in Nasal Cavity and Paranasal Sinus Carcinoma

TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Nonsense, TP53 Missense, and PIK3CA Mutation are the most common alterations in nasal cavity and paranasal sinus carcinoma [2].

Top Alterations in Nasal Cavity and Paranasal Sinus Carcinoma

Clinical Trials

View Clinical Trials for Nasal Cavity and Paranasal Sinus Carcinoma

There is 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains nasal cavity and paranasal sinus carcinoma as an inclusion criterion, 1 is phase 2 (1 open).

ABL1, BRAF, and DDR2 are the most frequent gene inclusion criteria for nasal cavity and paranasal sinus carcinoma clinical trials [3].

Trials Investigating Nasal Cavity And Paranasal Sinus Carcinoma by Gene and Recruiting Status

Afatinib, cabozantinib, and regorafenib are the most common interventions in nasal cavity and paranasal sinus carcinoma clinical trials.

Drugs Being Investigated in Nasal Cavity And Paranasal Sinus Carcinoma Trials by Recruiting Status

Significant Genes in Nasal Cavity and Paranasal Sinus Carcinoma

ABL1 +

ABL1 is altered in 4.76% of nasal cavity and paranasal sinus carcinoma patients [2].

ABL1 is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF +

BRAF is altered in 1.47% of nasal cavity and paranasal sinus carcinoma patients [2].

BRAF is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

DDR2 +

DDR2 is altered in 4.76% of nasal cavity and paranasal sinus carcinoma patients [2].

DDR2 is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR +

EGFR is altered in 7.14% of nasal cavity and paranasal sinus carcinoma patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EPHA2 +

EPHA2 is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 +

ERBB2 is altered in 1.41% of nasal cavity and paranasal sinus carcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB4 +

ERBB4 is altered in 1.54% of nasal cavity and paranasal sinus carcinoma patients [2].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 +

FGFR1 is altered in 4.84% of nasal cavity and paranasal sinus carcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 +

FGFR2 is altered in 3.03% of nasal cavity and paranasal sinus carcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 +

FLT1 is altered in 7.14% of nasal cavity and paranasal sinus carcinoma patients [2].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 +

FLT4 is altered in 5.77% of nasal cavity and paranasal sinus carcinoma patients [2].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FRK +

FRK is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FRK status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDR +

KDR is altered in 3.12% of nasal cavity and paranasal sinus carcinoma patients [2].

KDR is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT +

KIT is altered in 4.35% of nasal cavity and paranasal sinus carcinoma patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAPK11 +

MAPK11 is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA +

PDGFRA is altered in 2.9% of nasal cavity and paranasal sinus carcinoma patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB +

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 +

RAF1 is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RET +

RET is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TEK +

TEK is altered in 3.12% of nasal cavity and paranasal sinus carcinoma patients [2].

TEK is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TRNAK2 +

TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFA +

VEGFA is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFB +

VEGFB is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFC +

VEGFC is an inclusion eligibility criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Disease Details

Parent(s)

Paranasal Sinus and Nasal Cavity Cancer

Children

Nasal Cavity and Paranasal Sinus Neuroendocrine Carcinoma, Sinonasal Undifferentiated Carcinoma, Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Sinonasal Adenocarcinoma, and Nasal Cavity Carcinoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Nasal Cavity and Paranasal Sinus Carcinoma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Nasal Cavity and Paranasal Sinus Carcinoma

Disease Details

References

About

Molecular Medicine

Content Types